ArticleFrontiers in cell and developmental biology2025

The status of p53 affects the efficacy of PLK1 inhibitor BI6727 in prostate cancer cells.

Wenjing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.